Amedeo Smart

Free Medical Literature Service


 

Amedeo

Vaccines

  Free Subscription

Articles published in
Ann Intern Med
    August 2022
  1. BROPHY JM
    mRNA COVID-19 vaccines were linked to myocarditis at 28 d (0.15 to 10 excess events/100 000 vaccinated persons).
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0057.
    >> Share

  2. AISENBERG GM
    In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0056.
    >> Share

    July 2022
  3. FORSTER D
    COVID-19 diagnosis, but not vaccination, was linked to increased risk for immune-mediated neurologic events.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/J22-0048.
    >> Share

  4. FOLLMANN D, Janes HE, Buhule OD, Zhou H, et al
    Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/M22-1300.
    >> Share

    May 2022
  5. ROSENBLUM HG, Lewis RM, Gargano JW, Querec TD, et al
    Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M21-3798.
    >> Share

  6. PERKINS RB, Saslow D, Oliver K
    Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in Cancer.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-1309.
    >> Share

  7. ASSOUMOU SA, Peterson A, Ginman E, James T, et al
    Addressing Inequities in SARS-CoV-2 Vaccine Uptake: The Boston Medical Center Health System Experience.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-0028.
    >> Share

  8. KRYCHTIUK KA, Newby LK
    Moderna COVID-19 vaccine was linked to myocarditis or myopericarditis at 28 d (4.2 events/100 000 persons).
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0021.
    >> Share

  9. GRANWEHR BP
    In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at >/=7 d after the second dose.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0028.
    >> Share

  10. ZAHRADKA I, Petr V, Modos I, Magicova M, et al
    Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients : A Registry-Based Report.
    Ann Intern Med. 2022 May 3. doi: 10.7326/M21-2973.
    >> Share

    April 2022
  11. KOTTON CN
    Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/M22-1026.
    >> Share

  12. ROTHBERG MB
    Community-Acquired Pneumonia.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/AITC202204190.
    >> Share

    March 2022
  13. ZHENG C, Duffy J, Liu IA, Sy LS, et al
    Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data.
    Ann Intern Med. 2022 Mar 22. doi: 10.7326/M21-3023.
    >> Share

  14. LARSON EB, Nelson JC
    In older adults, use of a recombinant zoster vaccine was associated with Guillain-Barre syndrome.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0010.
    >> Share

  15. SILVESTRI EG, Borzak S
    In patients with MI or high-risk coronary disease, influenza vaccination reduced CV events at 12 mo.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0006.
    >> Share

    February 2022
  16. GAZIT S, Shlezinger R, Perez G, Lotan R, et al
    The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-4130.
    >> Share

  17. HVIID A, Hansen JV, Thiesson EM, Wohlfahrt J, et al
    Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-2452.
    >> Share

  18. KANG M, Yi Y, Li Y, Sun L, et al
    Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-3509.
    >> Share

  19. CHANG R
    Web Exclusive. Annals for Hospitalists Inpatient Notes - Another Way That Hospitalists Can Fight COVID-19.
    Ann Intern Med. 2022;175:HO2-HO3.
    >> Share

    January 2022
  20. TSUN LAI FT, Li X, Peng K, Huang L, et al
    Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study.
    Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3700.
    >> Share

  21. QASEEM A, Yost J, Etxeandia-Ikobaltzeta I, Forciea MA, et al
    What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3272.
    >> Share

  22. SEE I, Lale A, Marquez P, Streiff MB, et al
    Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
    Ann Intern Med. 2022 Jan 18. doi: 10.7326/M21-4502.
    >> Share

  23. CAILLARD S, Thaunat O, Benotmane I, Masset C, et al
    Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.
    Ann Intern Med. 2022 Jan 11. doi: 10.7326/L21-0598.
    >> Share

    December 2021
  24. IOANNOU GN, Locke ER, O'Hare AM, Bohnert ASB, et al
    COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study.
    Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3256.
    >> Share

  25. FAY MP, Hunsberger S, Follmann D
    Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy.
    Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3609.
    >> Share

  26. ANAND S, Montez-Rath ME, Han J, Garcia P, et al
    SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis.
    Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4176.
    >> Share

  27. LAINE C, Moyer DV, Cotton D
    COVID-19: Challenging Clinical Questions.
    Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4611.
    >> Share


  28. Correction: Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021;174:1780.
    >> Share

    November 2021
  29. KUMAR D, Ferreira VH, Hall VG, Hu Q, et al
    Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
    Ann Intern Med. 2021 Nov 23. doi: 10.7326/M21-3480.
    >> Share

  30. CHO BH, Weinbaum C, Tsai Y, Koppaka R, et al
    Influenza Vaccine Uptake and Missed Opportunities Among the Medicare-Covered Population With High-Risk Conditions During the 2018 to 2019 Influenza Season : A Retrospective Cohort Study.
    Ann Intern Med. 2021 Nov 16. doi: 10.7326/M21-1550.
    >> Share

  31. SARPATWARI A, Pandya A, Hyle EP, Persad G, et al
    COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?
    Ann Intern Med. 2021 Nov 9. doi: 10.7326/M21-3927.
    >> Share

  32. UYEKI TM
    Influenza.
    Ann Intern Med. 2021 Nov 9. doi: 10.7326/AITC202111160.
    >> Share

  33. MAKI DG
    Recommendations were made for diagnosis and management of allergic reactions to COVID-19 vaccines.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    >> Share

  34. GRANWEHR BP
    BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    >> Share

  35. SACKS HS
    The Novavax vaccine had 90% efficacy against COVID-19 >/=7 d after the second dose.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    >> Share

  36. DORFMAN AL, Murthy VL
    Web Exclusive. Annals for Hospitalists Inpatient Notes - Myocarditis After Vaccination for SARS-CoV-2.
    Ann Intern Med. 2021;174:HO2-HO3.
    >> Share

    October 2021
  37. HIMMELSTEIN J, Himmelstein DU, Woolhandler S, Dickman S, et al
    COVID-19-Related Care for Hispanic Elderly Adults With Limited English Proficiency.
    Ann Intern Med. 2021 Oct 26. doi: 10.7326/M21-2900.
    >> Share

  38. NOVAZZI F, Taborelli S, Baj A, Focosi D, et al
    Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing.
    Ann Intern Med. 2021 Oct 19. doi: 10.7326/M21-3486.
    >> Share

  39. MELMED GY, Botwin GJ, Sobhani K, Li D, et al
    Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-2483.
    >> Share

  40. LAINE C, Cotton D, Moyer DV
    COVID-19: Clinical and Public Health Implications of SARS-CoV-2 Immunology.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-3840.
    >> Share

  41. DELANEY SW, Essien UR, Navathe A
    Disparate Impact: How Colorblind Policies Exacerbate Black-White Health Inequities.
    Ann Intern Med. 2021;174:1450-1451.
    >> Share

    September 2021
  42. CURTIS JR, Cofield SS, Bridges SL Jr, Bassler J, et al
    The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
    Ann Intern Med. 2021 Sep 28. doi: 10.7326/M20-6928.
    >> Share

  43. REIF J, Heun-Johnson H, Tysinger B, Lakdawalla D, et al
    Measuring the COVID-19 Mortality Burden in the United States : A Microsimulation Study.
    Ann Intern Med. 2021 Sep 21. doi: 10.7326/M21-2239.
    >> Share

  44. AL-SAMKARI H, Leaf RK, Goodarzi K
    Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COV2.S Vaccination: A Case Report.
    Ann Intern Med. 2021 Sep 14. doi: 10.7326/L21-0427.
    >> Share

  45. MOGHADAS SM, Sah P, Shoukat A, Meyers LA, et al
    Population Immunity Against COVID-19 in the United States.
    Ann Intern Med. 2021 Sep 14. doi: 10.7326/M21-2721.
    >> Share

    August 2021
  46. DEEPAK P, Kim W, Paley MA, Yang M, et al
    Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-1757.
    >> Share

  47. PALTIEL AD, Schwartz JL
    Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-2965.
    >> Share

  48. CENTOR RM, Klompas M, Pearson M, Morris C, et al
    Annals On Call - The Case for Mandating COVID-19 Vaccines for Health Care Workers.
    Ann Intern Med. 2021 Aug 10:OC1. doi: 10.7326/A20-0020.
    >> Share

    July 2021
  49. EMANUEL EJ, Skorton DJ
    Mandating COVID-19 Vaccination for Health Care Workers.
    Ann Intern Med. 2021 Jul 30. doi: 10.7326/M21-3150.
    >> Share

  50. BUTT AA, Omer SB, Yan P, Shaikh OS, et al
    SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting.
    Ann Intern Med. 2021 Jul 20. doi: 10.7326/M21-1577.
    >> Share

  51. KLOMPAS M, Pearson M, Morris C
    The Case for Mandating COVID-19 Vaccines for Health Care Workers.
    Ann Intern Med. 2021 Jul 13. doi: 10.7326/M21-2366.
    >> Share

  52. SACKS HS
    The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at >/=14 d.
    Ann Intern Med. 2021 Jul 6. doi: 10.7326/ACPJ202107200.
    >> Share

    June 2021
  53. SANGLI S, Virani A, Cheronis N, Vannatter B, et al
    Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine.
    Ann Intern Med. 2021 Jun 29. doi: 10.7326/L21-0244.
    >> Share

  54. LAVANGE L, Adam SJ, Currier JS, Higgs ES, et al
    Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics.
    Ann Intern Med. 2021 Jun 29. doi: 10.7326/M21-1269.
    >> Share

  55. PISHKO AM, Cuker A
    Thrombosis After Vaccination With Messenger RNA-1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome?
    Ann Intern Med. 2021 Jun 29. doi: 10.7326/M21-2680.
    >> Share

  56. THORNTON JD, Dixon-Williams S, Huml A, Perzynski A, et al
    A Cross-Sectional Study of SARS-CoV-2 Vaccination Among Employees of an Urban Safety-Net Health Care System.
    Ann Intern Med. 2021 Jun 15. doi: 10.7326/M21-1513.
    >> Share

  57. MATHENY M, Maleque N, Channell N, Eisch AR, et al
    Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series.
    Ann Intern Med. 2021 Jun 15. doi: 10.7326/L21-0250.
    >> Share

  58. WERBEL WA, Boyarsky BJ, Ou MT, Massie AB, et al
    Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
    Ann Intern Med. 2021 Jun 15. doi: 10.7326/L21-0282.
    >> Share

  59. BILINSKI A, Salomon JA, Giardina J, Ciaranello A, et al
    Passing the Test: A Model-Based Analysis of Safe School-Reopening Strategies.
    Ann Intern Med. 2021 Jun 8. doi: 10.7326/M21-0600.
    >> Share

    May 2021
  60. CONNOLLY CM, Boyarsky BJ, Ruddy JA, Werbel WA, et al
    Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
    Ann Intern Med. 2021 May 25. doi: 10.7326/M21-1451.
    >> Share

  61. MARION O, Del Bello A, Abravanel F, Couat C, et al
    Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants.
    Ann Intern Med. 2021 May 25. doi: 10.7326/M21-1341.
    >> Share

  62. ARNOLD DT, Milne A, Samms E, Stadon L, et al
    Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series.
    Ann Intern Med. 2021 May 25. doi: 10.7326/M21-1976.
    >> Share

  63. IRFAN N, Chagla Z
    In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).
    Ann Intern Med. 2021 May 4. doi: 10.7326/ACPJ202105180.
    >> Share

    April 2021

  64. Correction: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.
    Ann Intern Med. 2021 Apr 20. doi: 10.7326/L21-0233.
    >> Share

  65. FOLLMANN D, Fintzi J, Fay MP, Janes HE, et al
    A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.
    Ann Intern Med. 2021 Apr 13. doi: 10.7326/M20-8149.
    >> Share

  66. MUSTAFA SS, Ramsey A, Staicu ML
    Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports.
    Ann Intern Med. 2021 Apr 6. doi: 10.7326/L21-0104.
    >> Share

    March 2021
  67. LAINE C, Cotton D, Moyer DV
    COVID-19 Vaccine: Practical Clinical Considerations.
    Ann Intern Med. 2021 Mar 26. doi: 10.7326/M21-1260.
    >> Share

  68. TROGEN B, Caplan A
    Risk Compensation and COVID-19 Vaccines.
    Ann Intern Med. 2021 Mar 2. doi: 10.7326/M20-8251.
    >> Share

  69. CHAGLA Z
    In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 >/=14 d after the 2nd dose.
    Ann Intern Med. 2021 Mar 2. doi: 10.7326/ACPJ202103160.
    >> Share

  70. CHAGLA Z
    In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
    Ann Intern Med. 2021 Mar 2. doi: 10.7326/ACPJ202103160.
    >> Share

  71. FREEDMAN MS, Bernstein H, Ault KA
    Recommended Adult Immunization Schedule, United States, 2021.
    Ann Intern Med. 2021;174:374-384.
    >> Share

    February 2021
  72. CENTOR RM, Riley LE
    Annals On Call - Pregnancy, Lactation, and the COVID-19 Vaccines.
    Ann Intern Med. 2021 Feb 23:OC1. doi: 10.7326/A20-0009.
    >> Share

  73. SALISCH NC, Stephenson KE, Williams K, Cox F, et al
    A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.
    Ann Intern Med. 2021 Feb 16. doi: 10.7326/M20-5306.
    >> Share

  74. OPEL DJ, Lo B, Peek ME
    Addressing Mistrust About COVID-19 Vaccines Among Patients of Color.
    Ann Intern Med. 2021 Feb 9. doi: 10.7326/M21-0055.
    >> Share

  75. GADOTH A, Halbrook M, Martin-Blais R, Gray A, et al
    Cross-sectional Assessment of COVID-19 Vaccine Acceptance Among Health Care Workers in Los Angeles.
    Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-7580.
    >> Share

  76. TROTTER AB, Abbott EK, Coyle R, Shen AK, et al
    Preparing for COVID-19 Vaccination: A Call to Action for Clinicians on Immunization Information Systems.
    Ann Intern Med. 2021 Feb 2. doi: 10.7326/M20-7725.
    >> Share

  77. CHAGLA Z
    The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 >/=7 days after the 2nd dose.
    Ann Intern Med. 2021 Feb 2. doi: 10.7326/ACPJ202102160.
    >> Share

    January 2021
  78. RILEY LE, Jamieson DJ
    Inclusion of Pregnant and Lactating Persons in COVID-19 Vaccination Efforts.
    Ann Intern Med. 2021 Jan 26. doi: 10.7326/M21-0173.
    >> Share

  79. FARRIS GE
    Annals Graphic Medicine - Dr. Mom: The Emotions of Getting the COVID-19 Vaccine.
    Ann Intern Med. 2021 Jan 26. doi: 10.7326/G20-0119.
    >> Share

  80. GREGORY JM, Moore DJ
    The Dual Burden of Type 1 Diabetes and COVID-19.
    Ann Intern Med. 2021 Jan 26. doi: 10.7326/M21-0367.
    >> Share

  81. LAINE C, Cotton D, Moyer DV
    COVID-19 Vaccine Distribution and Allocation: What Physicians Need to Know.
    Ann Intern Med. 2021 Jan 25. doi: 10.7326/M21-0331.
    >> Share

  82. CONNORS M, Graham BS, Lane HC, Fauci AS, et al
    SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.
    Ann Intern Med. 2021 Jan 19. doi: 10.7326/M21-0111.
    >> Share

  83. CENTOR RM, Manning KD
    Annals On Call - Vaccine Hesitancy: Choosing Our Battles.
    Ann Intern Med. 2021 Jan 19:OC1. doi: 10.7326/A20-0006.
    >> Share

  84. PALTIEL AD, Zheng A, Schwartz JL
    Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.
    Ann Intern Med. 2021 Jan 5. doi: 10.7326/M20-7866.
    >> Share

  85. CARRERA M, Lawler EC, White C
    Population Mortality and Laws Encouraging Influenza Vaccination for Hospital Workers.
    Ann Intern Med. 2021 Jan 5. doi: 10.7326/M20-0413.
    >> Share

  86. BARNABAS RV, Wald A
    A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose.
    Ann Intern Med. 2021 Jan 5. doi: 10.7326/M20-8060.
    >> Share

  87. BOLLYKY TJ
    U.S. COVID-19 Vaccination Challenges Go Beyond Supply.
    Ann Intern Med. 2021 Jan 5. doi: 10.7326/M20-8280.
    >> Share

  88. TUITE AR, Zhu L, Fisman DN, Salomon JA, et al
    Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply.
    Ann Intern Med. 2021 Jan 5. doi: 10.7326/M20-8137.
    >> Share

    December 2020
  89. LAINE C, Cotton D, Moyer DV
    COVID-19 Vaccine: Promoting Vaccine Acceptance.
    Ann Intern Med. 2020 Dec 21. doi: 10.7326/M20-8008.
    >> Share

  90. PALMER T, Cuschieri K
    Human Papillomavirus Immunization and the Elimination of Cervical Carcinoma.
    Ann Intern Med. 2020;173:935-936.
    >> Share

    November 2020
  91. CENTOR RM, Goepfert P
    Annals On Call - A Primer on COVID-19 Vaccines.
    Ann Intern Med. 2020 Nov 24:OC1. doi: 10.7326/A19-0044.
    >> Share

  92. MACPHERSON A, Hutchinson N, Schneider O, Oliviero E, et al
    Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
    Ann Intern Med. 2020 Nov 24. doi: 10.7326/M20-5350.
    >> Share

  93. DAL-RE R, Caplan AL, Gluud C, Porcher R, et al
    Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine.
    Ann Intern Med. 2020 Nov 20. doi: 10.7326/M20-7357.
    >> Share

    October 2020
  94. MEHROTRA DV, Janes HE, Fleming TR, Annunziato PW, et al
    Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.
    Ann Intern Med. 2020 Oct 22. doi: 10.7326/M20-6169.
    >> Share

  95. LAINE C, Cotton D, Moyer DV
    COVID-19 Vaccine: What Physicians Need to Know.
    Ann Intern Med. 2020 Oct 20. doi: 10.7326/M20-6841.
    >> Share

    September 2020
  96. BAUSSANO I, Tshomo U, Tenet V, Heideman DAM, et al
    Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
    Ann Intern Med. 2020 Sep 22. doi: 10.7326/M20-2849.
    >> Share

  97. LUDVIGSSON JF, Winell H, Sandin S, Cnattingius S, et al
    Maternal Influenza A(H1N1) Immunization During Pregnancy and Risk for Autism Spectrum Disorder in Offspring : A Cohort Study.
    Ann Intern Med. 2020 Sep 1. doi: 10.7326/M20-0167.
    >> Share

    August 2020
  98. CHOW EJ, Rolfes MA, O'Halloran A, Anderson EJ, et al
    Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults : A Cross-sectional Study.
    Ann Intern Med. 2020 Aug 25. doi: 10.7326/M20-1509.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016